{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:40Z","timestamp":1792896940858,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005954","name":"Children\u2019s Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001245","name":"Jeffrey Modell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaip.2018.10.049","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T22:15:33Z","timestamp":1545344133000},"page":"809-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders"],"prefix":"10.1016","volume":"7","author":[{"given":"Katherine M.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blachy J.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.10.049_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS phenotypic classification for primary immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib2","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2018.10.049_bib5","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","volume":"126","author":"Gennery","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2017-09-807487","article-title":"Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency","volume":"131","author":"Fox","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib7","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.bbmt.2015.06.015","article-title":"Significant transplantation-related mortality from respiratory virus infections within the first one hundred days in children after hematopoietic stem cell transplantation","volume":"21","author":"Hutspardol","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.10.049_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12026-010-8191-9","article-title":"Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes","volume":"49","author":"Buckley","year":"2011","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaip.2018.10.049_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10875-014-9994-6","article-title":"Patients with primary immunodeficiencies in pediatric intensive care unit: outcomes and mortality-related risk factors","volume":"34","author":"Odek","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib10","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T\u00a0cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib12","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for Adv, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2018.10.049_bib14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib15","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib17","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.10.049_bib20","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib21","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib22","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.10.049_bib24","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jcyt.2017.07.012","article-title":"Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant","volume":"19","author":"Sutrave","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib26","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2018.10.049_bib27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0033-1333749","article-title":"Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation","volume":"225","author":"Feucht","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jaip.2018.10.049_bib29","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.10.049_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib32","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.10.049_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.10.049_bib36","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2018.10.049_bib37","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib38","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaip.2018.10.049_bib39","first-page":"293","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaip.2018.10.049_bib40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1470-2045(05)70171-6","article-title":"Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation","volume":"6","author":"Wynn","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaip.2018.10.049_bib41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2018.10.049_bib42","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib43","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.bbmt.2018.04.030","article-title":"Antiviral T cells for adenovirus in the pretransplant period: a bridge therapy for severe combined immunodeficiency","volume":"24","author":"Miller","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.10.049_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10875-014-0125-1","article-title":"Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation","volume":"35","author":"Punwani","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/14653241003709686","article-title":"Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience","volume":"12","author":"Cruz","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib46","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib47","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.10.049_bib48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.10.049_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/mt.2014.48","article-title":"Systemic inflammatory response syndrome after administration of unmodified T lymphocytes","volume":"22","author":"Papadopoulou","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2018.10.049_bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08579.x","article-title":"Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease","volume":"154","author":"Qasim","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.10.049_bib52","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0198-8859(03)00028-4","article-title":"Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles","volume":"64","author":"Lacey","year":"2003","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib53","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1702656","article-title":"Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit","volume":"26","author":"Crooks","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.10.049_bib54","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcyt.2016.08.010","article-title":"Human parainfluenza virus-3 can be targeted by rapidly ex\u00a0vivo expanded T lymphocytes","volume":"18","author":"McLaughlin","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib55","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/jix358","article-title":"Immunologic profiling of human metapneumovirus for the development of targeted immunotherapy","volume":"216","author":"Tzannou","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jaip.2018.10.049_bib56","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1128\/JVI.02139-13","article-title":"Determining the breadth of the respiratory syncytial virus-specific T cell response","volume":"88","author":"McDermott","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jaip.2018.10.049_bib57","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jaci.2012.07.049","article-title":"Warts and all: human papillomavirus in primary immunodeficiencies","volume":"130","author":"Leiding","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.10.049_bib58","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(04)16457-X","article-title":"Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency","volume":"363","author":"Laffort","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.10.049_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jcyt.2017.11.010","article-title":"Human papilloma virus-specific T cells can be generated from naive T cells for use as an immunotherapeutic strategy for immunocompromised patients","volume":"20","author":"McCormack","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2018.10.049_bib61","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib62","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2014-11-608539","article-title":"Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation","volume":"125","author":"Cieri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcyt.2014.12.009","article-title":"Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation","volume":"17","author":"Orio","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaip.2018.10.049_bib64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib65","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.10.049_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco.2018.04.02","article-title":"Chimeric antigen receptor T cells, a savior with a high price","volume":"7","author":"de Lima Lopes","year":"2018","journal-title":"Chin Clin Oncol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818307219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818307219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:20:00Z","timestamp":1761974400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818307219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2213219818307219"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.10.049","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}